nodes	percent_of_prediction	percent_of_DWPC	metapath
Thalidomide—TNF—epilepsy syndrome	0.122	0.447	CbGaD
Thalidomide—CYP2C19—epilepsy syndrome	0.0929	0.341	CbGaD
Thalidomide—PTGS2—epilepsy syndrome	0.0579	0.212	CbGaD
Thalidomide—CYP2E1—Trimethadione—epilepsy syndrome	0.0182	0.044	CbGbCtD
Thalidomide—CYP2E1—Felbamate—epilepsy syndrome	0.0182	0.044	CbGbCtD
Thalidomide—CYP2E1—Clonazepam—epilepsy syndrome	0.0155	0.0375	CbGbCtD
Thalidomide—CYP3A5—Oxcarbazepine—epilepsy syndrome	0.0152	0.0368	CbGbCtD
Thalidomide—CYP1A1—Propofol—epilepsy syndrome	0.0133	0.0322	CbGbCtD
Thalidomide—CYP1A1—Phenobarbital—epilepsy syndrome	0.0127	0.0308	CbGbCtD
Thalidomide—CYP2E1—Rufinamide—epilepsy syndrome	0.0126	0.0305	CbGbCtD
Thalidomide—CYP2C19—Oxcarbazepine—epilepsy syndrome	0.0123	0.0297	CbGbCtD
Thalidomide—PTGS1—Diazepam—epilepsy syndrome	0.0121	0.0292	CbGbCtD
Thalidomide—CYP2C19—Felbamate—epilepsy syndrome	0.0114	0.0276	CbGbCtD
Thalidomide—CYP2C19—Trimethadione—epilepsy syndrome	0.0114	0.0276	CbGbCtD
Thalidomide—CYP2C19—Fosphenytoin—epilepsy syndrome	0.0107	0.026	CbGbCtD
Thalidomide—CYP2E1—Propofol—epilepsy syndrome	0.0103	0.0249	CbGbCtD
Thalidomide—CYP2E1—Phenobarbital—epilepsy syndrome	0.00984	0.0238	CbGbCtD
Thalidomide—CYP2E1—Midazolam—epilepsy syndrome	0.0097	0.0235	CbGbCtD
Thalidomide—CYP3A5—Carbamazepine—epilepsy syndrome	0.00956	0.0231	CbGbCtD
Thalidomide—PTGS1—Valproic Acid—epilepsy syndrome	0.00952	0.023	CbGbCtD
Thalidomide—CYP2C9—Trimethadione—epilepsy syndrome	0.00949	0.023	CbGbCtD
Thalidomide—CYP2E1—Diazepam—epilepsy syndrome	0.00933	0.0225	CbGbCtD
Thalidomide—CYP2C19—Clobazam—epilepsy syndrome	0.00931	0.0225	CbGbCtD
Thalidomide—CYP2C9—Fosphenytoin—epilepsy syndrome	0.00893	0.0216	CbGbCtD
Thalidomide—CYP3A5—Phenytoin—epilepsy syndrome	0.00858	0.0207	CbGbCtD
Thalidomide—CYP2C19—Carbamazepine—epilepsy syndrome	0.00771	0.0186	CbGbCtD
Thalidomide—CYP3A5—Phenobarbital—epilepsy syndrome	0.00764	0.0185	CbGbCtD
Thalidomide—CYP3A5—Midazolam—epilepsy syndrome	0.00754	0.0182	CbGbCtD
Thalidomide—CYP3A5—Diazepam—epilepsy syndrome	0.00725	0.0175	CbGbCtD
Thalidomide—CYP2C19—Primidone—epilepsy syndrome	0.0072	0.0174	CbGbCtD
Thalidomide—CYP1A2—Carbamazepine—epilepsy syndrome	0.00712	0.0172	CbGbCtD
Thalidomide—CYP2C19—Phenytoin—epilepsy syndrome	0.00692	0.0167	CbGbCtD
Thalidomide—CYP1A2—Primidone—epilepsy syndrome	0.00664	0.0161	CbGbCtD
Thalidomide—CYP2C19—Propofol—epilepsy syndrome	0.00645	0.0156	CbGbCtD
Thalidomide—CYP2C9—Carbamazepine—epilepsy syndrome	0.00641	0.0155	CbGbCtD
Thalidomide—CYP2C19—Phenobarbital—epilepsy syndrome	0.00617	0.0149	CbGbCtD
Thalidomide—CYP2C9—Primidone—epilepsy syndrome	0.00599	0.0145	CbGbCtD
Thalidomide—CYP1A2—Propofol—epilepsy syndrome	0.00595	0.0144	CbGbCtD
Thalidomide—CYP2C19—Diazepam—epilepsy syndrome	0.00585	0.0141	CbGbCtD
Thalidomide—CYP2C9—Phenytoin—epilepsy syndrome	0.00575	0.0139	CbGbCtD
Thalidomide—CYP3A5—Valproic Acid—epilepsy syndrome	0.00571	0.0138	CbGbCtD
Thalidomide—CYP2C19—Zonisamide—epilepsy syndrome	0.00571	0.0138	CbGbCtD
Thalidomide—CYP1A2—Phenobarbital—epilepsy syndrome	0.00569	0.0138	CbGbCtD
Thalidomide—CYP1A2—Diazepam—epilepsy syndrome	0.00539	0.013	CbGbCtD
Thalidomide—CYP2C9—Propofol—epilepsy syndrome	0.00536	0.013	CbGbCtD
Thalidomide—CYP2C9—Phenobarbital—epilepsy syndrome	0.00513	0.0124	CbGbCtD
Thalidomide—CYP2C9—Diazepam—epilepsy syndrome	0.00486	0.0117	CbGbCtD
Thalidomide—CYP2C19—Valproic Acid—epilepsy syndrome	0.00461	0.0111	CbGbCtD
Thalidomide—CYP1A2—Valproic Acid—epilepsy syndrome	0.00425	0.0103	CbGbCtD
Thalidomide—CYP2C19—Topiramate—epilepsy syndrome	0.00416	0.0101	CbGbCtD
Thalidomide—CYP2C9—Valproic Acid—epilepsy syndrome	0.00383	0.00926	CbGbCtD
Thalidomide—FGFR2—skull—epilepsy syndrome	0.00371	0.142	CbGeAlD
Thalidomide—FGFR2—hindbrain—epilepsy syndrome	0.00147	0.0559	CbGeAlD
Thalidomide—NFKB1—forebrain—epilepsy syndrome	0.00108	0.0412	CbGeAlD
Thalidomide—NFKB1—telencephalon—epilepsy syndrome	0.000993	0.0379	CbGeAlD
Thalidomide—CRBN—forebrain—epilepsy syndrome	0.000905	0.0345	CbGeAlD
Thalidomide—FGFR2—brainstem—epilepsy syndrome	0.00084	0.032	CbGeAlD
Thalidomide—CRBN—telencephalon—epilepsy syndrome	0.000832	0.0317	CbGeAlD
Thalidomide—FGFR2—forebrain—epilepsy syndrome	0.000811	0.0309	CbGeAlD
Thalidomide—FGFR2—telencephalon—epilepsy syndrome	0.000745	0.0284	CbGeAlD
Thalidomide—Pomalidomide—TNF—epilepsy syndrome	0.000734	0.354	CrCbGaD
Thalidomide—CRBN—medulla oblongata—epilepsy syndrome	0.000654	0.0249	CbGeAlD
Thalidomide—NFKB1—head—epilepsy syndrome	0.000618	0.0236	CbGeAlD
Thalidomide—PTGS1—ganglion—epilepsy syndrome	0.000614	0.0234	CbGeAlD
Thalidomide—CRBN—midbrain—epilepsy syndrome	0.000597	0.0228	CbGeAlD
Thalidomide—NFKB1—nervous system—epilepsy syndrome	0.000586	0.0224	CbGeAlD
Thalidomide—CRBN—spinal cord—epilepsy syndrome	0.000583	0.0222	CbGeAlD
Thalidomide—NFKB1—central nervous system—epilepsy syndrome	0.000564	0.0215	CbGeAlD
Thalidomide—NFKB1—cerebellum—epilepsy syndrome	0.000551	0.021	CbGeAlD
Thalidomide—FGFR2—spinal cord—epilepsy syndrome	0.000522	0.0199	CbGeAlD
Thalidomide—CRBN—head—epilepsy syndrome	0.000518	0.0198	CbGeAlD
Thalidomide—CRBN—nervous system—epilepsy syndrome	0.000491	0.0187	CbGeAlD
Thalidomide—CRBN—central nervous system—epilepsy syndrome	0.000473	0.018	CbGeAlD
Thalidomide—FGFR2—head—epilepsy syndrome	0.000464	0.0177	CbGeAlD
Thalidomide—CRBN—cerebellum—epilepsy syndrome	0.000462	0.0176	CbGeAlD
Thalidomide—NFKB1—brain—epilepsy syndrome	0.000448	0.0171	CbGeAlD
Thalidomide—FGFR2—nervous system—epilepsy syndrome	0.00044	0.0168	CbGeAlD
Thalidomide—FGFR2—central nervous system—epilepsy syndrome	0.000424	0.0162	CbGeAlD
Thalidomide—FGFR2—cerebellum—epilepsy syndrome	0.000414	0.0158	CbGeAlD
Thalidomide—CRBN—brain—epilepsy syndrome	0.000375	0.0143	CbGeAlD
Thalidomide—Lenalidomide—PTGS2—epilepsy syndrome	0.000375	0.181	CrCbGaD
Thalidomide—Pomalidomide—PTGS2—epilepsy syndrome	0.000349	0.168	CrCbGaD
Thalidomide—FGFR2—brain—epilepsy syndrome	0.000336	0.0128	CbGeAlD
Thalidomide—Lenalidomide—ABCB1—epilepsy syndrome	0.000319	0.154	CrCbGaD
Thalidomide—Pomalidomide—ABCB1—epilepsy syndrome	0.000297	0.143	CrCbGaD
Thalidomide—PTGS1—forebrain—epilepsy syndrome	0.000258	0.00983	CbGeAlD
Thalidomide—PTGS2—forebrain—epilepsy syndrome	0.000246	0.0094	CbGeAlD
Thalidomide—CYP2E1—telencephalon—epilepsy syndrome	0.000246	0.00938	CbGeAlD
Thalidomide—PTGS1—telencephalon—epilepsy syndrome	0.000237	0.00904	CbGeAlD
Thalidomide—PTGS2—telencephalon—epilepsy syndrome	0.000227	0.00864	CbGeAlD
Thalidomide—CYP2E1—medulla oblongata—epilepsy syndrome	0.000193	0.00737	CbGeAlD
Thalidomide—PTGS2—medulla oblongata—epilepsy syndrome	0.000178	0.00679	CbGeAlD
Thalidomide—CYP2E1—spinal cord—epilepsy syndrome	0.000172	0.00658	CbGeAlD
Thalidomide—CYP1A1—head—epilepsy syndrome	0.000168	0.00641	CbGeAlD
Thalidomide—PTGS1—spinal cord—epilepsy syndrome	0.000166	0.00633	CbGeAlD
Thalidomide—PTGS2—midbrain—epilepsy syndrome	0.000163	0.00621	CbGeAlD
Thalidomide—CYP1A1—nervous system—epilepsy syndrome	0.000159	0.00608	CbGeAlD
Thalidomide—PTGS2—spinal cord—epilepsy syndrome	0.000159	0.00605	CbGeAlD
Thalidomide—CYP1A1—central nervous system—epilepsy syndrome	0.000153	0.00585	CbGeAlD
Thalidomide—CYP2E1—head—epilepsy syndrome	0.000153	0.00584	CbGeAlD
Thalidomide—PTGS1—head—epilepsy syndrome	0.000148	0.00563	CbGeAlD
Thalidomide—CYP2E1—nervous system—epilepsy syndrome	0.000145	0.00554	CbGeAlD
Thalidomide—PTGS2—head—epilepsy syndrome	0.000141	0.00538	CbGeAlD
Thalidomide—PTGS1—nervous system—epilepsy syndrome	0.00014	0.00534	CbGeAlD
Thalidomide—CYP2E1—central nervous system—epilepsy syndrome	0.00014	0.00533	CbGeAlD
Thalidomide—CYP2E1—cerebellum—epilepsy syndrome	0.000137	0.00521	CbGeAlD
Thalidomide—PTGS1—central nervous system—epilepsy syndrome	0.000135	0.00514	CbGeAlD
Thalidomide—PTGS2—nervous system—epilepsy syndrome	0.000134	0.0051	CbGeAlD
Thalidomide—PTGS2—central nervous system—epilepsy syndrome	0.000129	0.00491	CbGeAlD
Thalidomide—PTGS2—cerebellum—epilepsy syndrome	0.000126	0.0048	CbGeAlD
Thalidomide—CYP1A1—brain—epilepsy syndrome	0.000122	0.00464	CbGeAlD
Thalidomide—CYP2E1—brain—epilepsy syndrome	0.000111	0.00423	CbGeAlD
Thalidomide—PTGS1—brain—epilepsy syndrome	0.000107	0.00408	CbGeAlD
Thalidomide—PTGS2—brain—epilepsy syndrome	0.000102	0.0039	CbGeAlD
Thalidomide—Diarrhoea—Clonazepam—epilepsy syndrome	1.94e-05	0.000103	CcSEcCtD
Thalidomide—Anaemia—Gabapentin—epilepsy syndrome	1.94e-05	0.000103	CcSEcCtD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Pregabalin—epilepsy syndrome	1.94e-05	0.000103	CcSEcCtD
Thalidomide—Hypotension—Valproic Acid—epilepsy syndrome	1.93e-05	0.000103	CcSEcCtD
Thalidomide—Asthenia—Carbamazepine—epilepsy syndrome	1.93e-05	0.000103	CcSEcCtD
Thalidomide—Agitation—Gabapentin—epilepsy syndrome	1.93e-05	0.000103	CcSEcCtD
Thalidomide—Diarrhoea—Phenytoin—epilepsy syndrome	1.93e-05	0.000103	CcSEcCtD
Thalidomide—Discomfort—Pregabalin—epilepsy syndrome	1.93e-05	0.000103	CcSEcCtD
Thalidomide—Nausea—Fosphenytoin—epilepsy syndrome	1.92e-05	0.000102	CcSEcCtD
Thalidomide—Diarrhoea—Oxcarbazepine—epilepsy syndrome	1.92e-05	0.000102	CcSEcCtD
Thalidomide—Erythema multiforme—Topiramate—epilepsy syndrome	1.92e-05	0.000102	CcSEcCtD
Thalidomide—Angioedema—Gabapentin—epilepsy syndrome	1.92e-05	0.000102	CcSEcCtD
Thalidomide—Hypersensitivity—Lamotrigine—epilepsy syndrome	1.92e-05	0.000102	CcSEcCtD
Thalidomide—Vomiting—Felbamate—epilepsy syndrome	1.91e-05	0.000102	CcSEcCtD
Thalidomide—Dry mouth—Pregabalin—epilepsy syndrome	1.91e-05	0.000101	CcSEcCtD
Thalidomide—Pruritus—Carbamazepine—epilepsy syndrome	1.9e-05	0.000101	CcSEcCtD
Thalidomide—Rash—Felbamate—epilepsy syndrome	1.9e-05	0.000101	CcSEcCtD
Thalidomide—Eye disorder—Topiramate—epilepsy syndrome	1.9e-05	0.000101	CcSEcCtD
Thalidomide—Dermatitis—Felbamate—epilepsy syndrome	1.9e-05	0.000101	CcSEcCtD
Thalidomide—Malaise—Gabapentin—epilepsy syndrome	1.89e-05	0.000101	CcSEcCtD
Thalidomide—Tinnitus—Topiramate—epilepsy syndrome	1.89e-05	0.000101	CcSEcCtD
Thalidomide—Vertigo—Gabapentin—epilepsy syndrome	1.89e-05	0.0001	CcSEcCtD
Thalidomide—Headache—Felbamate—epilepsy syndrome	1.88e-05	0.0001	CcSEcCtD
Thalidomide—Confusional state—Pregabalin—epilepsy syndrome	1.88e-05	0.0001	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Valproic Acid—epilepsy syndrome	1.88e-05	0.0001	CcSEcCtD
Thalidomide—Cardiac disorder—Topiramate—epilepsy syndrome	1.88e-05	0.0001	CcSEcCtD
Thalidomide—Syncope—Gabapentin—epilepsy syndrome	1.88e-05	0.0001	CcSEcCtD
Thalidomide—Leukopenia—Gabapentin—epilepsy syndrome	1.88e-05	0.0001	CcSEcCtD
Thalidomide—Dizziness—Clonazepam—epilepsy syndrome	1.88e-05	9.99e-05	CcSEcCtD
Thalidomide—Nausea—Vigabatrin—epilepsy syndrome	1.88e-05	9.98e-05	CcSEcCtD
Thalidomide—Vomiting—Zonisamide—epilepsy syndrome	1.87e-05	9.97e-05	CcSEcCtD
Thalidomide—Insomnia—Valproic Acid—epilepsy syndrome	1.87e-05	9.95e-05	CcSEcCtD
Thalidomide—Oedema—Pregabalin—epilepsy syndrome	1.87e-05	9.95e-05	CcSEcCtD
Thalidomide—Asthenia—Lamotrigine—epilepsy syndrome	1.87e-05	9.93e-05	CcSEcCtD
Thalidomide—Dizziness—Phenytoin—epilepsy syndrome	1.86e-05	9.92e-05	CcSEcCtD
Thalidomide—Rash—Zonisamide—epilepsy syndrome	1.86e-05	9.89e-05	CcSEcCtD
Thalidomide—Infection—Pregabalin—epilepsy syndrome	1.86e-05	9.88e-05	CcSEcCtD
Thalidomide—Paraesthesia—Valproic Acid—epilepsy syndrome	1.86e-05	9.88e-05	CcSEcCtD
Thalidomide—Palpitations—Gabapentin—epilepsy syndrome	1.86e-05	9.88e-05	CcSEcCtD
Thalidomide—Dermatitis—Zonisamide—epilepsy syndrome	1.86e-05	9.88e-05	CcSEcCtD
Thalidomide—Dizziness—Oxcarbazepine—epilepsy syndrome	1.85e-05	9.87e-05	CcSEcCtD
Thalidomide—Nausea—Diazepam—epilepsy syndrome	1.85e-05	9.83e-05	CcSEcCtD
Thalidomide—Loss of consciousness—Gabapentin—epilepsy syndrome	1.85e-05	9.82e-05	CcSEcCtD
Thalidomide—Headache—Zonisamide—epilepsy syndrome	1.85e-05	9.82e-05	CcSEcCtD
Thalidomide—Dyspnoea—Valproic Acid—epilepsy syndrome	1.84e-05	9.81e-05	CcSEcCtD
Thalidomide—Diarrhoea—Carbamazepine—epilepsy syndrome	1.84e-05	9.8e-05	CcSEcCtD
Thalidomide—Angiopathy—Topiramate—epilepsy syndrome	1.84e-05	9.8e-05	CcSEcCtD
Thalidomide—Pruritus—Lamotrigine—epilepsy syndrome	1.84e-05	9.8e-05	CcSEcCtD
Thalidomide—Shock—Pregabalin—epilepsy syndrome	1.84e-05	9.79e-05	CcSEcCtD
Thalidomide—Somnolence—Valproic Acid—epilepsy syndrome	1.84e-05	9.78e-05	CcSEcCtD
Thalidomide—Immune system disorder—Topiramate—epilepsy syndrome	1.83e-05	9.76e-05	CcSEcCtD
Thalidomide—Nervous system disorder—Pregabalin—epilepsy syndrome	1.83e-05	9.75e-05	CcSEcCtD
Thalidomide—Cough—Gabapentin—epilepsy syndrome	1.83e-05	9.75e-05	CcSEcCtD
Thalidomide—Thrombocytopenia—Pregabalin—epilepsy syndrome	1.83e-05	9.74e-05	CcSEcCtD
Thalidomide—Mediastinal disorder—Topiramate—epilepsy syndrome	1.83e-05	9.73e-05	CcSEcCtD
Thalidomide—Tachycardia—Pregabalin—epilepsy syndrome	1.82e-05	9.71e-05	CcSEcCtD
Thalidomide—Chills—Topiramate—epilepsy syndrome	1.82e-05	9.69e-05	CcSEcCtD
Thalidomide—Dyspepsia—Valproic Acid—epilepsy syndrome	1.82e-05	9.68e-05	CcSEcCtD
Thalidomide—Convulsion—Gabapentin—epilepsy syndrome	1.82e-05	9.68e-05	CcSEcCtD
Thalidomide—Skin disorder—Pregabalin—epilepsy syndrome	1.82e-05	9.66e-05	CcSEcCtD
Thalidomide—Hypertension—Gabapentin—epilepsy syndrome	1.81e-05	9.65e-05	CcSEcCtD
Thalidomide—Hyperhidrosis—Pregabalin—epilepsy syndrome	1.81e-05	9.62e-05	CcSEcCtD
Thalidomide—Vomiting—Clonazepam—epilepsy syndrome	1.8e-05	9.61e-05	CcSEcCtD
Thalidomide—Decreased appetite—Valproic Acid—epilepsy syndrome	1.8e-05	9.56e-05	CcSEcCtD
Thalidomide—Alopecia—Topiramate—epilepsy syndrome	1.79e-05	9.54e-05	CcSEcCtD
Thalidomide—Vomiting—Phenytoin—epilepsy syndrome	1.79e-05	9.54e-05	CcSEcCtD
Thalidomide—Rash—Clonazepam—epilepsy syndrome	1.79e-05	9.53e-05	CcSEcCtD
Thalidomide—Dermatitis—Clonazepam—epilepsy syndrome	1.79e-05	9.52e-05	CcSEcCtD
Thalidomide—Arthralgia—Gabapentin—epilepsy syndrome	1.79e-05	9.51e-05	CcSEcCtD
Thalidomide—Myalgia—Gabapentin—epilepsy syndrome	1.79e-05	9.51e-05	CcSEcCtD
Thalidomide—Chest pain—Gabapentin—epilepsy syndrome	1.79e-05	9.51e-05	CcSEcCtD
Thalidomide—Nausea—Felbamate—epilepsy syndrome	1.79e-05	9.51e-05	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Valproic Acid—epilepsy syndrome	1.78e-05	9.5e-05	CcSEcCtD
Thalidomide—Vomiting—Oxcarbazepine—epilepsy syndrome	1.78e-05	9.49e-05	CcSEcCtD
Thalidomide—Fatigue—Valproic Acid—epilepsy syndrome	1.78e-05	9.49e-05	CcSEcCtD
Thalidomide—Anxiety—Gabapentin—epilepsy syndrome	1.78e-05	9.48e-05	CcSEcCtD
Thalidomide—Anorexia—Pregabalin—epilepsy syndrome	1.78e-05	9.48e-05	CcSEcCtD
Thalidomide—Dizziness—Carbamazepine—epilepsy syndrome	1.78e-05	9.47e-05	CcSEcCtD
Thalidomide—Diarrhoea—Lamotrigine—epilepsy syndrome	1.78e-05	9.47e-05	CcSEcCtD
Thalidomide—Headache—Clonazepam—epilepsy syndrome	1.78e-05	9.47e-05	CcSEcCtD
Thalidomide—Rash—Phenytoin—epilepsy syndrome	1.78e-05	9.46e-05	CcSEcCtD
Thalidomide—Mental disorder—Topiramate—epilepsy syndrome	1.78e-05	9.46e-05	CcSEcCtD
Thalidomide—Dermatitis—Phenytoin—epilepsy syndrome	1.78e-05	9.45e-05	CcSEcCtD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Gabapentin—epilepsy syndrome	1.78e-05	9.45e-05	CcSEcCtD
Thalidomide—Rash—Oxcarbazepine—epilepsy syndrome	1.77e-05	9.41e-05	CcSEcCtD
Thalidomide—Pain—Valproic Acid—epilepsy syndrome	1.77e-05	9.41e-05	CcSEcCtD
Thalidomide—Constipation—Valproic Acid—epilepsy syndrome	1.77e-05	9.41e-05	CcSEcCtD
Thalidomide—Dermatitis—Oxcarbazepine—epilepsy syndrome	1.77e-05	9.4e-05	CcSEcCtD
Thalidomide—Headache—Phenytoin—epilepsy syndrome	1.77e-05	9.4e-05	CcSEcCtD
Thalidomide—Malnutrition—Topiramate—epilepsy syndrome	1.77e-05	9.4e-05	CcSEcCtD
Thalidomide—Discomfort—Gabapentin—epilepsy syndrome	1.77e-05	9.4e-05	CcSEcCtD
Thalidomide—Headache—Oxcarbazepine—epilepsy syndrome	1.76e-05	9.35e-05	CcSEcCtD
Thalidomide—Nausea—Zonisamide—epilepsy syndrome	1.75e-05	9.31e-05	CcSEcCtD
Thalidomide—Dry mouth—Gabapentin—epilepsy syndrome	1.75e-05	9.31e-05	CcSEcCtD
Thalidomide—Hypotension—Pregabalin—epilepsy syndrome	1.75e-05	9.29e-05	CcSEcCtD
Thalidomide—Flatulence—Topiramate—epilepsy syndrome	1.74e-05	9.26e-05	CcSEcCtD
Thalidomide—Tension—Topiramate—epilepsy syndrome	1.73e-05	9.23e-05	CcSEcCtD
Thalidomide—Dysgeusia—Topiramate—epilepsy syndrome	1.73e-05	9.21e-05	CcSEcCtD
Thalidomide—Confusional state—Gabapentin—epilepsy syndrome	1.73e-05	9.2e-05	CcSEcCtD
Thalidomide—Dizziness—Lamotrigine—epilepsy syndrome	1.72e-05	9.16e-05	CcSEcCtD
Thalidomide—Nervousness—Topiramate—epilepsy syndrome	1.72e-05	9.13e-05	CcSEcCtD
Thalidomide—Oedema—Gabapentin—epilepsy syndrome	1.71e-05	9.12e-05	CcSEcCtD
Thalidomide—Vomiting—Carbamazepine—epilepsy syndrome	1.71e-05	9.11e-05	CcSEcCtD
Thalidomide—Back pain—Topiramate—epilepsy syndrome	1.71e-05	9.09e-05	CcSEcCtD
Thalidomide—Feeling abnormal—Valproic Acid—epilepsy syndrome	1.7e-05	9.07e-05	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Pregabalin—epilepsy syndrome	1.7e-05	9.06e-05	CcSEcCtD
Thalidomide—Infection—Gabapentin—epilepsy syndrome	1.7e-05	9.06e-05	CcSEcCtD
Thalidomide—Muscle spasms—Topiramate—epilepsy syndrome	1.7e-05	9.04e-05	CcSEcCtD
Thalidomide—Rash—Carbamazepine—epilepsy syndrome	1.7e-05	9.03e-05	CcSEcCtD
Thalidomide—Dermatitis—Carbamazepine—epilepsy syndrome	1.7e-05	9.02e-05	CcSEcCtD
Thalidomide—Gastrointestinal pain—Valproic Acid—epilepsy syndrome	1.69e-05	9e-05	CcSEcCtD
Thalidomide—Insomnia—Pregabalin—epilepsy syndrome	1.69e-05	9e-05	CcSEcCtD
Thalidomide—Nausea—Clonazepam—epilepsy syndrome	1.69e-05	8.98e-05	CcSEcCtD
Thalidomide—Headache—Carbamazepine—epilepsy syndrome	1.69e-05	8.97e-05	CcSEcCtD
Thalidomide—Shock—Gabapentin—epilepsy syndrome	1.69e-05	8.97e-05	CcSEcCtD
Thalidomide—Nervous system disorder—Gabapentin—epilepsy syndrome	1.68e-05	8.94e-05	CcSEcCtD
Thalidomide—Paraesthesia—Pregabalin—epilepsy syndrome	1.68e-05	8.93e-05	CcSEcCtD
Thalidomide—Thrombocytopenia—Gabapentin—epilepsy syndrome	1.68e-05	8.93e-05	CcSEcCtD
Thalidomide—Nausea—Phenytoin—epilepsy syndrome	1.67e-05	8.91e-05	CcSEcCtD
Thalidomide—Tachycardia—Gabapentin—epilepsy syndrome	1.67e-05	8.9e-05	CcSEcCtD
Thalidomide—Dyspnoea—Pregabalin—epilepsy syndrome	1.67e-05	8.87e-05	CcSEcCtD
Thalidomide—Nausea—Oxcarbazepine—epilepsy syndrome	1.67e-05	8.87e-05	CcSEcCtD
Thalidomide—Vision blurred—Topiramate—epilepsy syndrome	1.66e-05	8.86e-05	CcSEcCtD
Thalidomide—Skin disorder—Gabapentin—epilepsy syndrome	1.66e-05	8.86e-05	CcSEcCtD
Thalidomide—Somnolence—Pregabalin—epilepsy syndrome	1.66e-05	8.84e-05	CcSEcCtD
Thalidomide—Hyperhidrosis—Gabapentin—epilepsy syndrome	1.66e-05	8.82e-05	CcSEcCtD
Thalidomide—Tremor—Topiramate—epilepsy syndrome	1.65e-05	8.81e-05	CcSEcCtD
Thalidomide—Vomiting—Lamotrigine—epilepsy syndrome	1.65e-05	8.8e-05	CcSEcCtD
Thalidomide—Urticaria—Valproic Acid—epilepsy syndrome	1.64e-05	8.74e-05	CcSEcCtD
Thalidomide—Rash—Lamotrigine—epilepsy syndrome	1.64e-05	8.73e-05	CcSEcCtD
Thalidomide—Ill-defined disorder—Topiramate—epilepsy syndrome	1.64e-05	8.72e-05	CcSEcCtD
Thalidomide—Dermatitis—Lamotrigine—epilepsy syndrome	1.64e-05	8.72e-05	CcSEcCtD
Thalidomide—Body temperature increased—Valproic Acid—epilepsy syndrome	1.63e-05	8.7e-05	CcSEcCtD
Thalidomide—Abdominal pain—Valproic Acid—epilepsy syndrome	1.63e-05	8.7e-05	CcSEcCtD
Thalidomide—Anorexia—Gabapentin—epilepsy syndrome	1.63e-05	8.69e-05	CcSEcCtD
Thalidomide—Anaemia—Topiramate—epilepsy syndrome	1.63e-05	8.69e-05	CcSEcCtD
Thalidomide—Headache—Lamotrigine—epilepsy syndrome	1.63e-05	8.67e-05	CcSEcCtD
Thalidomide—Decreased appetite—Pregabalin—epilepsy syndrome	1.62e-05	8.65e-05	CcSEcCtD
Thalidomide—Agitation—Topiramate—epilepsy syndrome	1.62e-05	8.64e-05	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Pregabalin—epilepsy syndrome	1.61e-05	8.59e-05	CcSEcCtD
Thalidomide—Fatigue—Pregabalin—epilepsy syndrome	1.61e-05	8.58e-05	CcSEcCtD
Thalidomide—Hypotension—Gabapentin—epilepsy syndrome	1.6e-05	8.52e-05	CcSEcCtD
Thalidomide—Nausea—Carbamazepine—epilepsy syndrome	1.6e-05	8.51e-05	CcSEcCtD
Thalidomide—Constipation—Pregabalin—epilepsy syndrome	1.6e-05	8.51e-05	CcSEcCtD
Thalidomide—Pain—Pregabalin—epilepsy syndrome	1.6e-05	8.51e-05	CcSEcCtD
Thalidomide—Malaise—Topiramate—epilepsy syndrome	1.59e-05	8.48e-05	CcSEcCtD
Thalidomide—Vertigo—Topiramate—epilepsy syndrome	1.59e-05	8.45e-05	CcSEcCtD
Thalidomide—Syncope—Topiramate—epilepsy syndrome	1.58e-05	8.43e-05	CcSEcCtD
Thalidomide—Leukopenia—Topiramate—epilepsy syndrome	1.58e-05	8.42e-05	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Gabapentin—epilepsy syndrome	1.56e-05	8.31e-05	CcSEcCtD
Thalidomide—Palpitations—Topiramate—epilepsy syndrome	1.56e-05	8.31e-05	CcSEcCtD
Thalidomide—Loss of consciousness—Topiramate—epilepsy syndrome	1.55e-05	8.26e-05	CcSEcCtD
Thalidomide—Insomnia—Gabapentin—epilepsy syndrome	1.55e-05	8.25e-05	CcSEcCtD
Thalidomide—Nausea—Lamotrigine—epilepsy syndrome	1.54e-05	8.22e-05	CcSEcCtD
Thalidomide—Cough—Topiramate—epilepsy syndrome	1.54e-05	8.2e-05	CcSEcCtD
Thalidomide—Feeling abnormal—Pregabalin—epilepsy syndrome	1.54e-05	8.2e-05	CcSEcCtD
Thalidomide—Paraesthesia—Gabapentin—epilepsy syndrome	1.54e-05	8.19e-05	CcSEcCtD
Thalidomide—Convulsion—Topiramate—epilepsy syndrome	1.53e-05	8.15e-05	CcSEcCtD
Thalidomide—Gastrointestinal pain—Pregabalin—epilepsy syndrome	1.53e-05	8.13e-05	CcSEcCtD
Thalidomide—Dyspnoea—Gabapentin—epilepsy syndrome	1.53e-05	8.13e-05	CcSEcCtD
Thalidomide—Hypertension—Topiramate—epilepsy syndrome	1.52e-05	8.12e-05	CcSEcCtD
Thalidomide—Somnolence—Gabapentin—epilepsy syndrome	1.52e-05	8.11e-05	CcSEcCtD
Thalidomide—Hypersensitivity—Valproic Acid—epilepsy syndrome	1.52e-05	8.11e-05	CcSEcCtD
Thalidomide—Dyspepsia—Gabapentin—epilepsy syndrome	1.51e-05	8.03e-05	CcSEcCtD
Thalidomide—Myalgia—Topiramate—epilepsy syndrome	1.5e-05	8e-05	CcSEcCtD
Thalidomide—Chest pain—Topiramate—epilepsy syndrome	1.5e-05	8e-05	CcSEcCtD
Thalidomide—Arthralgia—Topiramate—epilepsy syndrome	1.5e-05	8e-05	CcSEcCtD
Thalidomide—Anxiety—Topiramate—epilepsy syndrome	1.5e-05	7.98e-05	CcSEcCtD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Topiramate—epilepsy syndrome	1.49e-05	7.95e-05	CcSEcCtD
Thalidomide—Decreased appetite—Gabapentin—epilepsy syndrome	1.49e-05	7.93e-05	CcSEcCtD
Thalidomide—Discomfort—Topiramate—epilepsy syndrome	1.49e-05	7.91e-05	CcSEcCtD
Thalidomide—Urticaria—Pregabalin—epilepsy syndrome	1.48e-05	7.9e-05	CcSEcCtD
Thalidomide—Asthenia—Valproic Acid—epilepsy syndrome	1.48e-05	7.89e-05	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Gabapentin—epilepsy syndrome	1.48e-05	7.87e-05	CcSEcCtD
Thalidomide—Fatigue—Gabapentin—epilepsy syndrome	1.48e-05	7.86e-05	CcSEcCtD
Thalidomide—Abdominal pain—Pregabalin—epilepsy syndrome	1.48e-05	7.86e-05	CcSEcCtD
Thalidomide—Body temperature increased—Pregabalin—epilepsy syndrome	1.48e-05	7.86e-05	CcSEcCtD
Thalidomide—Dry mouth—Topiramate—epilepsy syndrome	1.47e-05	7.83e-05	CcSEcCtD
Thalidomide—Pain—Gabapentin—epilepsy syndrome	1.47e-05	7.8e-05	CcSEcCtD
Thalidomide—Constipation—Gabapentin—epilepsy syndrome	1.47e-05	7.8e-05	CcSEcCtD
Thalidomide—Pruritus—Valproic Acid—epilepsy syndrome	1.46e-05	7.78e-05	CcSEcCtD
Thalidomide—Confusional state—Topiramate—epilepsy syndrome	1.45e-05	7.74e-05	CcSEcCtD
Thalidomide—Oedema—Topiramate—epilepsy syndrome	1.44e-05	7.67e-05	CcSEcCtD
Thalidomide—Infection—Topiramate—epilepsy syndrome	1.43e-05	7.62e-05	CcSEcCtD
Thalidomide—Shock—Topiramate—epilepsy syndrome	1.42e-05	7.55e-05	CcSEcCtD
Thalidomide—Diarrhoea—Valproic Acid—epilepsy syndrome	1.41e-05	7.53e-05	CcSEcCtD
Thalidomide—Nervous system disorder—Topiramate—epilepsy syndrome	1.41e-05	7.53e-05	CcSEcCtD
Thalidomide—Feeling abnormal—Gabapentin—epilepsy syndrome	1.41e-05	7.52e-05	CcSEcCtD
Thalidomide—Thrombocytopenia—Topiramate—epilepsy syndrome	1.41e-05	7.51e-05	CcSEcCtD
Thalidomide—Tachycardia—Topiramate—epilepsy syndrome	1.41e-05	7.49e-05	CcSEcCtD
Thalidomide—Gastrointestinal pain—Gabapentin—epilepsy syndrome	1.4e-05	7.46e-05	CcSEcCtD
Thalidomide—Skin disorder—Topiramate—epilepsy syndrome	1.4e-05	7.45e-05	CcSEcCtD
Thalidomide—Hyperhidrosis—Topiramate—epilepsy syndrome	1.39e-05	7.42e-05	CcSEcCtD
Thalidomide—Hypersensitivity—Pregabalin—epilepsy syndrome	1.38e-05	7.33e-05	CcSEcCtD
Thalidomide—Anorexia—Topiramate—epilepsy syndrome	1.37e-05	7.31e-05	CcSEcCtD
Thalidomide—Dizziness—Valproic Acid—epilepsy syndrome	1.37e-05	7.28e-05	CcSEcCtD
Thalidomide—Urticaria—Gabapentin—epilepsy syndrome	1.36e-05	7.25e-05	CcSEcCtD
Thalidomide—Abdominal pain—Gabapentin—epilepsy syndrome	1.35e-05	7.21e-05	CcSEcCtD
Thalidomide—Body temperature increased—Gabapentin—epilepsy syndrome	1.35e-05	7.21e-05	CcSEcCtD
Thalidomide—Hypotension—Topiramate—epilepsy syndrome	1.35e-05	7.17e-05	CcSEcCtD
Thalidomide—Asthenia—Pregabalin—epilepsy syndrome	1.34e-05	7.14e-05	CcSEcCtD
Thalidomide—Pruritus—Pregabalin—epilepsy syndrome	1.32e-05	7.04e-05	CcSEcCtD
Thalidomide—Vomiting—Valproic Acid—epilepsy syndrome	1.31e-05	7e-05	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Topiramate—epilepsy syndrome	1.31e-05	6.99e-05	CcSEcCtD
Thalidomide—Insomnia—Topiramate—epilepsy syndrome	1.3e-05	6.94e-05	CcSEcCtD
Thalidomide—Rash—Valproic Acid—epilepsy syndrome	1.3e-05	6.94e-05	CcSEcCtD
Thalidomide—Dermatitis—Valproic Acid—epilepsy syndrome	1.3e-05	6.93e-05	CcSEcCtD
Thalidomide—Headache—Valproic Acid—epilepsy syndrome	1.29e-05	6.89e-05	CcSEcCtD
Thalidomide—Paraesthesia—Topiramate—epilepsy syndrome	1.29e-05	6.89e-05	CcSEcCtD
Thalidomide—Dyspnoea—Topiramate—epilepsy syndrome	1.29e-05	6.84e-05	CcSEcCtD
Thalidomide—Somnolence—Topiramate—epilepsy syndrome	1.28e-05	6.82e-05	CcSEcCtD
Thalidomide—Diarrhoea—Pregabalin—epilepsy syndrome	1.28e-05	6.81e-05	CcSEcCtD
Thalidomide—Dyspepsia—Topiramate—epilepsy syndrome	1.27e-05	6.75e-05	CcSEcCtD
Thalidomide—Hypersensitivity—Gabapentin—epilepsy syndrome	1.26e-05	6.72e-05	CcSEcCtD
Thalidomide—Decreased appetite—Topiramate—epilepsy syndrome	1.25e-05	6.67e-05	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Topiramate—epilepsy syndrome	1.24e-05	6.62e-05	CcSEcCtD
Thalidomide—Fatigue—Topiramate—epilepsy syndrome	1.24e-05	6.62e-05	CcSEcCtD
Thalidomide—Dizziness—Pregabalin—epilepsy syndrome	1.24e-05	6.58e-05	CcSEcCtD
Thalidomide—Pain—Topiramate—epilepsy syndrome	1.23e-05	6.56e-05	CcSEcCtD
Thalidomide—Constipation—Topiramate—epilepsy syndrome	1.23e-05	6.56e-05	CcSEcCtD
Thalidomide—Asthenia—Gabapentin—epilepsy syndrome	1.23e-05	6.54e-05	CcSEcCtD
Thalidomide—Nausea—Valproic Acid—epilepsy syndrome	1.23e-05	6.54e-05	CcSEcCtD
Thalidomide—Pruritus—Gabapentin—epilepsy syndrome	1.21e-05	6.45e-05	CcSEcCtD
Thalidomide—Vomiting—Pregabalin—epilepsy syndrome	1.19e-05	6.32e-05	CcSEcCtD
Thalidomide—Feeling abnormal—Topiramate—epilepsy syndrome	1.19e-05	6.32e-05	CcSEcCtD
Thalidomide—Gastrointestinal pain—Topiramate—epilepsy syndrome	1.18e-05	6.27e-05	CcSEcCtD
Thalidomide—Rash—Pregabalin—epilepsy syndrome	1.18e-05	6.27e-05	CcSEcCtD
Thalidomide—Dermatitis—Pregabalin—epilepsy syndrome	1.18e-05	6.27e-05	CcSEcCtD
Thalidomide—Diarrhoea—Gabapentin—epilepsy syndrome	1.17e-05	6.24e-05	CcSEcCtD
Thalidomide—Headache—Pregabalin—epilepsy syndrome	1.17e-05	6.23e-05	CcSEcCtD
Thalidomide—Urticaria—Topiramate—epilepsy syndrome	1.15e-05	6.1e-05	CcSEcCtD
Thalidomide—Abdominal pain—Topiramate—epilepsy syndrome	1.14e-05	6.07e-05	CcSEcCtD
Thalidomide—Body temperature increased—Topiramate—epilepsy syndrome	1.14e-05	6.07e-05	CcSEcCtD
Thalidomide—Dizziness—Gabapentin—epilepsy syndrome	1.13e-05	6.03e-05	CcSEcCtD
Thalidomide—Nausea—Pregabalin—epilepsy syndrome	1.11e-05	5.91e-05	CcSEcCtD
Thalidomide—Vomiting—Gabapentin—epilepsy syndrome	1.09e-05	5.8e-05	CcSEcCtD
Thalidomide—Rash—Gabapentin—epilepsy syndrome	1.08e-05	5.75e-05	CcSEcCtD
Thalidomide—Dermatitis—Gabapentin—epilepsy syndrome	1.08e-05	5.75e-05	CcSEcCtD
Thalidomide—Headache—Gabapentin—epilepsy syndrome	1.07e-05	5.71e-05	CcSEcCtD
Thalidomide—Hypersensitivity—Topiramate—epilepsy syndrome	1.06e-05	5.65e-05	CcSEcCtD
Thalidomide—Asthenia—Topiramate—epilepsy syndrome	1.03e-05	5.51e-05	CcSEcCtD
Thalidomide—Pruritus—Topiramate—epilepsy syndrome	1.02e-05	5.43e-05	CcSEcCtD
Thalidomide—Nausea—Gabapentin—epilepsy syndrome	1.02e-05	5.42e-05	CcSEcCtD
Thalidomide—Diarrhoea—Topiramate—epilepsy syndrome	9.86e-06	5.25e-05	CcSEcCtD
Thalidomide—Dizziness—Topiramate—epilepsy syndrome	9.53e-06	5.07e-05	CcSEcCtD
Thalidomide—Vomiting—Topiramate—epilepsy syndrome	9.17e-06	4.88e-05	CcSEcCtD
Thalidomide—Rash—Topiramate—epilepsy syndrome	9.09e-06	4.84e-05	CcSEcCtD
Thalidomide—Dermatitis—Topiramate—epilepsy syndrome	9.08e-06	4.83e-05	CcSEcCtD
Thalidomide—Headache—Topiramate—epilepsy syndrome	9.03e-06	4.81e-05	CcSEcCtD
Thalidomide—Nausea—Topiramate—epilepsy syndrome	8.56e-06	4.56e-05	CcSEcCtD
Thalidomide—FGFR2—Immune System—BCL2—epilepsy syndrome	3.33e-06	3.41e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—NOS1—epilepsy syndrome	3.31e-06	3.39e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—TXNRD1—epilepsy syndrome	3.29e-06	3.37e-05	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—epilepsy syndrome	3.28e-06	3.36e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CCR5—epilepsy syndrome	3.28e-06	3.36e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—CYP2C19—epilepsy syndrome	3.26e-06	3.34e-05	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—AKT1—epilepsy syndrome	3.26e-06	3.34e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CACNA1A—epilepsy syndrome	3.26e-06	3.34e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ALDH7A1—epilepsy syndrome	3.26e-06	3.34e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—CYP2C19—epilepsy syndrome	3.26e-06	3.33e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—RELA—epilepsy syndrome	3.25e-06	3.33e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—CYP11A1—epilepsy syndrome	3.24e-06	3.32e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—FGF2—epilepsy syndrome	3.24e-06	3.32e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—CYP11A1—epilepsy syndrome	3.23e-06	3.31e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—TSC2—epilepsy syndrome	3.21e-06	3.29e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—HTR2A—epilepsy syndrome	3.21e-06	3.29e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—AGT—epilepsy syndrome	3.21e-06	3.29e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—AQP1—epilepsy syndrome	3.19e-06	3.27e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—MTOR—epilepsy syndrome	3.19e-06	3.27e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ST3GAL3—epilepsy syndrome	3.19e-06	3.27e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—KCNJ11—epilepsy syndrome	3.17e-06	3.25e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CHRM3—epilepsy syndrome	3.17e-06	3.25e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—ABCG2—epilepsy syndrome	3.16e-06	3.23e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—HBEGF—epilepsy syndrome	3.16e-06	3.23e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—APOE—epilepsy syndrome	3.15e-06	3.22e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ADSL—epilepsy syndrome	3.12e-06	3.2e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—ALB—epilepsy syndrome	3.12e-06	3.19e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—CYP2D6—epilepsy syndrome	3.11e-06	3.18e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—IL1B—epilepsy syndrome	3.1e-06	3.18e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—AKT3—epilepsy syndrome	3.1e-06	3.17e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—KDR—epilepsy syndrome	3.08e-06	3.16e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—CYP2C19—epilepsy syndrome	3.08e-06	3.15e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—epilepsy syndrome	3.07e-06	3.14e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GLUL—epilepsy syndrome	3.06e-06	3.14e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—CYP11A1—epilepsy syndrome	3.06e-06	3.13e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—TSC2—epilepsy syndrome	3.05e-06	3.12e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—AGT—epilepsy syndrome	3.05e-06	3.12e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—POMC—epilepsy syndrome	3.03e-06	3.11e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—ADAM10—epilepsy syndrome	3.03e-06	3.1e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CACNA1D—epilepsy syndrome	3.01e-06	3.08e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—JUN—epilepsy syndrome	3.01e-06	3.08e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—APOE—epilepsy syndrome	2.98e-06	3.06e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—PRKCB—epilepsy syndrome	2.97e-06	3.04e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—ADRA2A—epilepsy syndrome	2.96e-06	3.03e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—IL6ST—epilepsy syndrome	2.95e-06	3.03e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—AGT—epilepsy syndrome	2.95e-06	3.02e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—MTOR—epilepsy syndrome	2.95e-06	3.02e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—BCHE—epilepsy syndrome	2.95e-06	3.02e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—IL1B—epilepsy syndrome	2.94e-06	3.01e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—CYP2D6—epilepsy syndrome	2.93e-06	3e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—KDR—epilepsy syndrome	2.92e-06	3e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—PTGS2—epilepsy syndrome	2.92e-06	2.99e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—CYP2D6—epilepsy syndrome	2.92e-06	2.99e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—HMOX1—epilepsy syndrome	2.91e-06	2.98e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—APOE—epilepsy syndrome	2.89e-06	2.96e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—KCNJ11—epilepsy syndrome	2.89e-06	2.96e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CHRM3—epilepsy syndrome	2.89e-06	2.96e-05	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—AKT1—epilepsy syndrome	2.88e-06	2.95e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—CAT—epilepsy syndrome	2.87e-06	2.94e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—JUN—epilepsy syndrome	2.85e-06	2.92e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—CDC42—epilepsy syndrome	2.83e-06	2.89e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—PRKCB—epilepsy syndrome	2.81e-06	2.88e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—TXNRD1—epilepsy syndrome	2.81e-06	2.88e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—SLC2A1—epilepsy syndrome	2.81e-06	2.88e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—IL6ST—epilepsy syndrome	2.8e-06	2.87e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—ABCB1—epilepsy syndrome	2.8e-06	2.86e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—ADRA2A—epilepsy syndrome	2.79e-06	2.85e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PLCB1—epilepsy syndrome	2.78e-06	2.85e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—ADRA2A—epilepsy syndrome	2.78e-06	2.85e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—BCHE—epilepsy syndrome	2.77e-06	2.84e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—TH—epilepsy syndrome	2.77e-06	2.84e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—BCHE—epilepsy syndrome	2.77e-06	2.84e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—ALB—epilepsy syndrome	2.77e-06	2.83e-05	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—AKT1—epilepsy syndrome	2.76e-06	2.83e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—CYP2D6—epilepsy syndrome	2.76e-06	2.83e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—AQP1—epilepsy syndrome	2.73e-06	2.8e-05	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—AKT1—epilepsy syndrome	2.73e-06	2.8e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—POMC—epilepsy syndrome	2.7e-06	2.77e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—SRC—epilepsy syndrome	2.7e-06	2.76e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—AGT—epilepsy syndrome	2.69e-06	2.76e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—SLC2A1—epilepsy syndrome	2.65e-06	2.71e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CCL2—epilepsy syndrome	2.64e-06	2.71e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—SLC2A1—epilepsy syndrome	2.64e-06	2.7e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—APOE—epilepsy syndrome	2.64e-06	2.7e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—ADRA2A—epilepsy syndrome	2.63e-06	2.69e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—epilepsy syndrome	2.62e-06	2.69e-05	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—AKT1—epilepsy syndrome	2.62e-06	2.68e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PLCB1—epilepsy syndrome	2.62e-06	2.68e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—BCHE—epilepsy syndrome	2.61e-06	2.68e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PLCB1—epilepsy syndrome	2.61e-06	2.68e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—TH—epilepsy syndrome	2.61e-06	2.67e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—TH—epilepsy syndrome	2.6e-06	2.67e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—GPX1—epilepsy syndrome	2.6e-06	2.66e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—HES1—epilepsy syndrome	2.59e-06	2.65e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—ABCG2—epilepsy syndrome	2.58e-06	2.65e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—POMC—epilepsy syndrome	2.56e-06	2.63e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—SRC—epilepsy syndrome	2.56e-06	2.62e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—FYN—epilepsy syndrome	2.52e-06	2.58e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CCL2—epilepsy syndrome	2.51e-06	2.57e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—H2AFX—epilepsy syndrome	2.51e-06	2.57e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CYP11A1—epilepsy syndrome	2.5e-06	2.56e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—SLC2A1—epilepsy syndrome	2.49e-06	2.56e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—POMC—epilepsy syndrome	2.48e-06	2.54e-05	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—AKT1—epilepsy syndrome	2.48e-06	2.54e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CHRM3—epilepsy syndrome	2.47e-06	2.53e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—KCNJ11—epilepsy syndrome	2.47e-06	2.53e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PLCB1—epilepsy syndrome	2.47e-06	2.53e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—TH—epilepsy syndrome	2.46e-06	2.52e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—epilepsy syndrome	2.42e-06	2.48e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—YWHAZ—epilepsy syndrome	2.42e-06	2.48e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—FGF2—epilepsy syndrome	2.39e-06	2.45e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—SRC—epilepsy syndrome	2.36e-06	2.42e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—ABCG2—epilepsy syndrome	2.35e-06	2.41e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—CCR5—epilepsy syndrome	2.33e-06	2.38e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—HMOX1—epilepsy syndrome	2.31e-06	2.37e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—AGT—epilepsy syndrome	2.3e-06	2.35e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CYP2C19—epilepsy syndrome	2.29e-06	2.35e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—CAT—epilepsy syndrome	2.28e-06	2.34e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CYP11A1—epilepsy syndrome	2.28e-06	2.34e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—AGT—epilepsy syndrome	2.28e-06	2.33e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—FGF2—epilepsy syndrome	2.27e-06	2.32e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—POMC—epilepsy syndrome	2.26e-06	2.32e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—ALB—epilepsy syndrome	2.26e-06	2.32e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CYP2D6—epilepsy syndrome	2.26e-06	2.31e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—APOE—epilepsy syndrome	2.25e-06	2.31e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—APOE—epilepsy syndrome	2.23e-06	2.29e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—ABCB1—epilepsy syndrome	2.22e-06	2.27e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—RELA—epilepsy syndrome	2.22e-06	2.27e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—HMOX1—epilepsy syndrome	2.18e-06	2.23e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—MTOR—epilepsy syndrome	2.18e-06	2.23e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—HMOX1—epilepsy syndrome	2.17e-06	2.22e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—TSC2—epilepsy syndrome	2.16e-06	2.22e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—ADRA2A—epilepsy syndrome	2.15e-06	2.2e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—CAT—epilepsy syndrome	2.15e-06	2.2e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—CAT—epilepsy syndrome	2.14e-06	2.2e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—BCHE—epilepsy syndrome	2.14e-06	2.19e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—APOE—epilepsy syndrome	2.12e-06	2.17e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—RELA—epilepsy syndrome	2.1e-06	2.16e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—ABCB1—epilepsy syndrome	2.09e-06	2.14e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—ABCB1—epilepsy syndrome	2.08e-06	2.14e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—ALB—epilepsy syndrome	2.06e-06	2.11e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—MTOR—epilepsy syndrome	2.06e-06	2.11e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—GPX1—epilepsy syndrome	2.06e-06	2.11e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CYP2D6—epilepsy syndrome	2.06e-06	2.11e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—HMOX1—epilepsy syndrome	2.05e-06	2.1e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—SLC2A1—epilepsy syndrome	2.04e-06	2.09e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—CAT—epilepsy syndrome	2.02e-06	2.07e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PLCB1—epilepsy syndrome	2.02e-06	2.07e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ABCG2—epilepsy syndrome	2.01e-06	2.06e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—TH—epilepsy syndrome	2.01e-06	2.06e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CASP3—epilepsy syndrome	2e-06	2.05e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—IL6ST—epilepsy syndrome	1.99e-06	2.04e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—epilepsy syndrome	1.98e-06	2.03e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—NOS2—epilepsy syndrome	1.97e-06	2.02e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—ABCB1—epilepsy syndrome	1.97e-06	2.02e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CYP2C19—epilepsy syndrome	1.96e-06	2.01e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—ADRA2A—epilepsy syndrome	1.96e-06	2.01e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—BCHE—epilepsy syndrome	1.95e-06	2e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CYP11A1—epilepsy syndrome	1.95e-06	2e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—JUN—epilepsy syndrome	1.94e-06	1.99e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—GPX1—epilepsy syndrome	1.94e-06	1.99e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—GPX1—epilepsy syndrome	1.94e-06	1.99e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—POMC—epilepsy syndrome	1.93e-06	1.98e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—POMC—epilepsy syndrome	1.92e-06	1.96e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CASP3—epilepsy syndrome	1.9e-06	1.94e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—MMP9—epilepsy syndrome	1.89e-06	1.94e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—SLC2A1—epilepsy syndrome	1.86e-06	1.91e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—JUN—epilepsy syndrome	1.84e-06	1.89e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PLCB1—epilepsy syndrome	1.84e-06	1.89e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—TH—epilepsy syndrome	1.83e-06	1.88e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—GPX1—epilepsy syndrome	1.83e-06	1.88e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—AGT—epilepsy syndrome	1.81e-06	1.85e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—epilepsy syndrome	1.81e-06	1.85e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—MMP9—epilepsy syndrome	1.79e-06	1.84e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—APOE—epilepsy syndrome	1.77e-06	1.82e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—ALB—epilepsy syndrome	1.76e-06	1.81e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CYP2D6—epilepsy syndrome	1.76e-06	1.8e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—ALB—epilepsy syndrome	1.75e-06	1.79e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—SRC—epilepsy syndrome	1.74e-06	1.79e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—AGT—epilepsy syndrome	1.7e-06	1.74e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—AGT—epilepsy syndrome	1.7e-06	1.74e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—VEGFA—epilepsy syndrome	1.7e-06	1.74e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—HMOX1—epilepsy syndrome	1.68e-06	1.72e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—AKT1—epilepsy syndrome	1.68e-06	1.72e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ADRA2A—epilepsy syndrome	1.67e-06	1.72e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—APOE—epilepsy syndrome	1.67e-06	1.71e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—BCHE—epilepsy syndrome	1.67e-06	1.71e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—APOE—epilepsy syndrome	1.67e-06	1.71e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CAT—epilepsy syndrome	1.66e-06	1.7e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—SRC—epilepsy syndrome	1.65e-06	1.69e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—ABCB1—epilepsy syndrome	1.61e-06	1.65e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—VEGFA—epilepsy syndrome	1.61e-06	1.65e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—FGF2—epilepsy syndrome	1.61e-06	1.65e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—AGT—epilepsy syndrome	1.61e-06	1.64e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—SLC2A1—epilepsy syndrome	1.59e-06	1.63e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—AKT1—epilepsy syndrome	1.59e-06	1.63e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PLCB1—epilepsy syndrome	1.57e-06	1.61e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—APOE—epilepsy syndrome	1.57e-06	1.61e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—TH—epilepsy syndrome	1.57e-06	1.61e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—epilepsy syndrome	1.54e-06	1.58e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—HMOX1—epilepsy syndrome	1.53e-06	1.57e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PTGS2—epilepsy syndrome	1.53e-06	1.57e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—POMC—epilepsy syndrome	1.52e-06	1.56e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CAT—epilepsy syndrome	1.51e-06	1.55e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—GPX1—epilepsy syndrome	1.5e-06	1.53e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—ABCB1—epilepsy syndrome	1.47e-06	1.51e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—AKT1—epilepsy syndrome	1.47e-06	1.5e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—MTOR—epilepsy syndrome	1.46e-06	1.5e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—POMC—epilepsy syndrome	1.43e-06	1.47e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—POMC—epilepsy syndrome	1.43e-06	1.47e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—ALB—epilepsy syndrome	1.39e-06	1.42e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GPX1—epilepsy syndrome	1.37e-06	1.4e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—POMC—epilepsy syndrome	1.35e-06	1.38e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—AGT—epilepsy syndrome	1.31e-06	1.35e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—HMOX1—epilepsy syndrome	1.31e-06	1.34e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—ALB—epilepsy syndrome	1.31e-06	1.34e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—ALB—epilepsy syndrome	1.3e-06	1.34e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CAT—epilepsy syndrome	1.29e-06	1.32e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—APOE—epilepsy syndrome	1.29e-06	1.32e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ABCB1—epilepsy syndrome	1.26e-06	1.29e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—ALB—epilepsy syndrome	1.23e-06	1.26e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—AGT—epilepsy syndrome	1.2e-06	1.23e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—APOE—epilepsy syndrome	1.17e-06	1.2e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—SRC—epilepsy syndrome	1.17e-06	1.2e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GPX1—epilepsy syndrome	1.17e-06	1.2e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PTGS2—epilepsy syndrome	1.14e-06	1.17e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PTGS2—epilepsy syndrome	1.14e-06	1.17e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—POMC—epilepsy syndrome	1.11e-06	1.13e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—AKT1—epilepsy syndrome	1.08e-06	1.11e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PTGS2—epilepsy syndrome	1.08e-06	1.1e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—AKT1—epilepsy syndrome	1.03e-06	1.05e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—AGT—epilepsy syndrome	1.02e-06	1.05e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—POMC—epilepsy syndrome	1.01e-06	1.03e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—ALB—epilepsy syndrome	1.01e-06	1.03e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—APOE—epilepsy syndrome	1e-06	1.03e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—ALB—epilepsy syndrome	9.19e-07	9.42e-06	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PTGS2—epilepsy syndrome	8.82e-07	9.04e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—POMC—epilepsy syndrome	8.62e-07	8.83e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PTGS2—epilepsy syndrome	8.04e-07	8.24e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ALB—epilepsy syndrome	7.86e-07	8.05e-06	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—AKT1—epilepsy syndrome	7.69e-07	7.88e-06	CbGpPWpGaD
Thalidomide—PTGS2—Disease—AKT1—epilepsy syndrome	7.29e-07	7.47e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PTGS2—epilepsy syndrome	6.87e-07	7.04e-06	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—AKT1—epilepsy syndrome	6.1e-07	6.25e-06	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—AKT1—epilepsy syndrome	5.75e-07	5.89e-06	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—AKT1—epilepsy syndrome	5.73e-07	5.87e-06	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—AKT1—epilepsy syndrome	5.42e-07	5.55e-06	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—AKT1—epilepsy syndrome	4.43e-07	4.54e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—AKT1—epilepsy syndrome	4.04e-07	4.14e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—AKT1—epilepsy syndrome	3.45e-07	3.54e-06	CbGpPWpGaD
